BAG3 and glioblastoma: Several lines of evidence point at a key function of BAG3 in therapy‐resistant cancers such as TNBC and GBM, and we recently identified a completely novel deciliating function of BAG3 in both tumor entities,23 representing an interesting putative mechanism further driving the aggressiveness of these tumors.